FDA Requests Suicidality Event Review For Epilepsy Drugs

FDA is requesting that 14 manufacturers of anti-epileptic drugs re-examine clinical trial data to identify potential suicide-related adverse events. The analyses will be modeled on the agency’s recent re-examination of antidepressant data. FDA’s request to epilepsy drug sponsors follows suicidality signals seen in some trials.